
GOODRX HOLDINGS INC-CLASS A
GDRXNASDAQTrading Snapshot
- Day Range
- $3.61 โ $3.67
- 52-Week Range
- $1.77 โ $5.81
- Volume
- $3.46B
- Avg Volume
- $2.70B
- Shares Outstanding
- 338.7M
- Next Earnings
- Sep 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $797M
- Last Q Revenue
- $200M
- P/E Ratio
- 76.8
- P/S Ratio
- 1.6x
- EPS (TTM)
- $0.05
- Dividend Yield
- โ
Why Investors Own GDRX
- โHigh-growth profile โ revenue up +24.3% YoY with expanding US Equity exposure.
- โHealthy economics โ 59% gross margin and 24% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GOODRX HOLDINGS INC-CLASS A
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope
GoodRx rebounds from $2.50 with improved traction and new offerings, but valuation and risk stay balanced. Click here to read an analysis of GDRX stock now.
TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsAubrey Reynolds - Director of Investor RelationsWendy...

GoodRx (NASDAQ:GDRX) Q2 2026: Subscription and Pharma Direct Growth Lift Shares Despite Revenue Decline
GoodRx Q2 results beat estimates; shares rise 4% as subscription and Pharma Direct revenue surge, offsetting core prescription decline.
GoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M Est
GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $765.000 million-$785.000 million to $790.000 million-$805.000 million vs $775.751 million estimate.
GoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M Estimate
GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.09 per share from the same period last year.